Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Daiichi Sankyo

AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.

Investors Business Daily

3 Healthcare Stocks Positioned for Major Gains in 2024

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

StockNews.com

Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection

Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

Barchart

Urgent call for breast cancer drug to stop women’s lives being cut short

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The Independent UK

Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

Barchart

Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Investors Business Daily

New breast cancer treatment not approved for NHS use

The health spending watchdog said the ‘the cost-effectiveness estimates were too high for it to be recommended for use in the NHS’.

The Independent UK

AstraZeneca Surges As It Takes A Shot At Gilead's Second-Biggest Cancer Drug

AstraZeneca and Daiichi Sankyo said Friday their breast cancer treatment outperformed chemo in a Phase 3 study, and AZN stock jumped.

Investors Business Daily

AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment

AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.

Investors Business Daily

AstraZeneca stock value falls by nearly £14bn after cancer drug trial results

Shares close down 8% on concerns that new lung cancer drug may not be as successful as hoped

The Guardian - UK

IBD Stock Of The Day AstraZeneca Stalls As Gilead Looks To Take Its Breast Cancer Market

AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming.

Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours:

Chicago Sun-Times

For some with breast cancer, the drug Enhertu could mean living longer, researchers report

Though not a cure, the findings announced in Chicago mark the first time a drug targeting a protein that drives breast cancer growth is shown to work against tumors with very low levels of the protein.

Benzinga

FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer

The FDA has approved AstraZeneca plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

112 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.